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Abstract: Insulin resistance and impaired beta-cell function are primary defects that occur early 
in the course of development of type 2 diabetes. Insulin resistance leads to hyperinsulinemia 
in order to maintain normal glucose tolerance. In most cases of type 2 diabetes, beta-cell 
dysfunction  develops  subsequent  to  the  development  of  insulin  resistance,  and  it  is  not 
until such beta-cell dysfunction develops that any abnormality in glucose tolerance is seen. 
Insulin resistance is a primary defect in type 2 diabetes. The risk of coronary heart disease is 
significantly increased in patients with type 2 diabetes. Cardiovascular disease causes 80% 
of all diabetic mortality, and in 75% of those cases, it is a result of coronary atherosclerosis. 
These points provide a rationale for early and aggressive management of cardiovascular risk 
in patients with diabetes. Thiazolidinediones represent an effective tool for targeting some 
features of this increased risk as they decrease insulin resistance and can prevent and/or delay 
diabetes progression.
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Pathophysiology of diabetic complications: 
implications for goals of therapy
Background
Type 2 diabetes is a metabolic disorder in which the abnormal metabolic environment 
signaled by hyperglycemia (hemoglobin A1C [HbA1c]) is a continuous risk factor for 
associated complications. There is no A1c threshold, and the risk of complications (eg, 
retinal, renal, neural, cardiovascular [CV], and cutaneous) becomes worse with longer 
diabetes duration.1 Many pathways are implicated in the causation of both microvascular 
and macrovascular complications. Brownlee’s unified theory2 suggests that a combina-
tion of factors is at work (eg, including elements of oxidative stress and endothelial 
dysfunction). Another aspect of disease development includes the individual’s risk for 
complication susceptibility via his or her genetic and ethnic background and acquired 
factors.3 Implications of this understanding are that a strategy of glucose control, early 
initiation of therapy, treatment of inflammation, endothelial dysfunction, and comor-
bidities is likely to decrease both microvascular and macrovascular complications.
In the pivotal Diabetes Control and Complications Trial (DCCT), investigators 
compared the use of intensive therapy with conventional treatment among 1,441 patients 
with type 1 diabetes.4 The mean follow-up was 6.5 years between 1983 and 1993. In 
DCCT, intensive blood glucose control significantly reduced the risk of the develop-
ment of microvascular disease (retinopathy 76%, nephropathy 50%, and neuropathy Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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60%). When the DCCT ended, researchers continued to study 
more than 90% of the participants for a mean of 17 years. 
The follow-up study, Epidemiology of Diabetes Interventions 
and Complications (EDIC), revealed a 42% reduced risk in 
cardiovascular disease (CVD) events and a 57% reduced risk 
of nonfatal myocardial infarction (MI), stroke, or death from 
CV causes associated with intensive treatment.5 The United 
Kingdom Prospective Diabetes Study (UKPDS)1 10 years 
after it ended and the Steno study6 found a 50% reduction 
in CV outcomes at 8 years and a 30% reduction in mortality 
at 13 years associated with treating glucose, blood pressure, 
and lipids to goal levels.
Recent studies suggesting otherwise, including Veterans 
Affairs Diabetes Trial (VADT),7 Action in Diabetes and 
Vascular Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation (ADVANCE),8 and Action 
to Control Cardiovascular Risk in Diabetes (ACCORD),9 
actually confirm this in those patients with shorter duration 
of diabetes and with no significant preexisting microvasuclar 
or macrovascular complications. The negative results of these 
3 studies as a whole can be explained by a poor choice of 
medications (eg, the use of sulfonylureas in ADVANCE), 
hypoglycemia, and weight gain with poor processes and 
methods of care (eg, ACCORD).10–12 Additionally, patients 
included in these trials may have had tissues that were past 
the metabolic point of no return by virtue of longer diabetes 
duration and significant preexisting damage.13,14
insulin resistance
Insulin resistance is a primary defect in type 2 diabetes. 
As reported by Haffner et al,15 92% of patients with type 
2 diabetes have insulin resistance. It can be defined as an 
impaired response to the physiological effects of insulin, 
including those on glucose, lipid, and protein metabolism, 
and the effects on vascular endothelial function.
Before the manifestation of the metabolic defects that lead 
to type 2 diabetes, fasting and postprandial insulin levels are 
similar and constant. As noted by Kendall and Bergenstal 
from the International Diabetes Center in Park Nicollet, 
Minneapolis, for the majority of patients who develop type 2 
diabetes, insulin resistance leads to compensatory increases in 
circulating insulin, thereby preventing an increase in glucose 
levels.16 As time progresses, the insulin resistance reaches 
a peak and stabilizes, while the compensatory increase in 
insulin continues to prevent fasting glucose levels from 
becoming abnormal. Their work and others have shown that, 
eventually, because of either early beta cell dysfunction or a 
genetic limitation of beta cell capacity, beta cell compensa-
tion cannot keep up with the increased demand. Postprandial 
and ultimately fasting glucose levels become abnormal as a 
limitation in insulin response is reached.16
Beta cell failure
Many patients who are insulin resistant do not manifest 
hyperglycemia because their ability to secrete insulin remains 
intact. However, functional defects in glucose-stimulated 
insulin secretion by beta cells, when combined with 
insulin resistance, can lead to impaired glucose tolerance, 
hyperglycemia, or type 2 diabetes. Beta cell function is 
progressively lost during the course of development of type 2 
diabetes. Data suggest that the onset of beta cell dysfunction 
associated with diabetes occurs well before the development 
of hyperglycemia and may begin years before the diagnosis of 
the disease. By the time diabetes is diagnosed, up to 50% 
of beta cell function may already be lost. The extent of 
beta cell function remaining is critical because therapeutic 
approaches to the prevention or treatment of diabetes are 
more effective earlier in the disease, most likely because 
the beta cell response at this time is more robust.17 Although 
glucose stimulates beta cells to secrete insulin, it may 
also modify beta cell function in a deleterious manner, ie, 
glucotoxicity or glucose desensitization may occur, which 
results in a decrease in insulin secretion. Animal models of 
diabetes have suggested that changes in lipid metabolism 
may contribute to the development of beta cell dysfunction. 
The role of lipotoxicity in humans with diabetes requires 
further research.18
A variety of theories for progressive beta cell failure 
have been proposed as explanations for the pathogenesis 
and progression of type 2 diabetes. A reduction in beta cell 
mass may help explain the impairment in maximal secretory 
capacity for insulin. This reduction may be caused by one or 
more factors: the rate of apoptosis (programmed cell death) 
may increase secondary to a deranged metabolic state, such 
as elevated levels of glucose or free fatty acids. In the nor-
mal pancreas, beta cell proliferation and neogenesis balance 
apoptosis. Under certain conditions such as hyperglycemia, 
the rate of apoptosis may outpace that of beta cell prolifera-
tion, resulting in a net loss of beta cells. Amyloid deposits 
have long been suspected as a potential cause of reduced beta 
cell mass. Although this relationship is difficult to study in 
humans, a variety of in vivo animal and in vitro experiments 
demonstrate that these deposits can be deleterious to beta 
cell function.19Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Emergence of thiazolidinediones
When thiazolidinediones (TZDs or glitazones) were intro-
duced, they represented a new class of oral agents with a 
novel mechanism of action that reduced insulin resistance 
and improved glycemic control. Glitazones act as agonists 
of nuclear receptors called peroxisome proliferator-activated 
receptors-gamma (PPAR-gamma) to enhance the actions of 
insulin, leading to improvement in insulin-dependent glucose 
disposal and reductions in hepatic glucose output.20
Because of the natural history of diabetes progression,1 
it is imperative that physicians act aggressively and early to 
control/treat the disease (even prediabetes), which, by defini-
tion, will delay or even prevent complications. The presented, 
but unpublished, ACT-Now study by DeFronzo21 seems to 
confirm smaller trials22 that suggest delay in developing 
diabetes in patients with impaired glucose tolerance. TZD’s 
durability of effect was shown in the 3-year stable A1C data 
from A Diabetes Outcome Progression Trial (ADOPT).23
Pioglitazone (Actos®; Takeda, Deerfield, IL, USA), 
alone and in combination, has been shown to be effective at 
improving glycemic control. Pioglitazone exerts additional ben-
eficial effects on blood pressure, microalbumin, inflammation, 
endothelial dysfunction, and lipids. The GLAI24 investigators 
found that pioglitazone and rosiglitazone have significantly 
different effects on plasma lipids independent of glycemic con-
trol or concomitant lipid-lowering or other antihyperglycemic 
therapy. Pioglitazone compared with rosiglitazone is associated 
with significant improvements in triglycerides, high-density 
lipoprotein cholesterol (HDL-C), low-density lipoprotein 
(LDL) particle concentration, and LDL particle size.
Side effects
edema
Safety concerns that have been raised with TZDs include the 
risk of fluid retention (mostly related to PPAR-gamma effect 
on salt and water retention by the kidney) and congestive 
heart failure (CHF), most likely to occur in those patients 
with diastolic dysfunction. The pioglitazone prescribing 
information warns that the agent, like other TZDs, can 
cause fluid retention when used alone or in combination 
with other antidiabetic agents, including insulin.25 Fluid 
retention may lead to or exacerbate CHF. It has been shown 
that the occurrence of CHF in patients taking TZDs may be 
a result of increased plasma volume unmasking previously 
asymptomatic and unrecognized diastolic dysfunction.26 
Only a minority of edema cases reported in glitazone-treated 
diabetic patients are associated with CHF.27
In a retrospective cohort study of 16,417 Medicare 
beneficiaries with diabetes discharged after hospitalization 
for heart failure, Masoudi et al28 showed that TZDs were 
associated with reduced mortality. Mortality among those 
patients receiving TZD therapy (mean age 75.9 years, 
n = 2,226) was significantly lower compared with patients 
receiving no insulin-sensitizing therapy (mean age 77 years, 
n = 12,069). The adjusted hazard ratio (HR) was 0.87 (95% 
confidence interval [CI], 0.80–0.94). Thus, the issue of CHF 
is dissociated from the agent’s general benefit in cardiac 
function.
Clinical experience has taught us that a no-added-salt diet 
markedly reduces the risk of edema in this population. Hydro-
chlorothiazide, amilioride, and spironolactone are preferred 
over furosemide for the treatment of mild edema.29 Clinically, 
we have also seen prevention and treatment of edema with 
ranolazine, a drug that improves diastolic dysfunction. This 
disconnect between edema, CHF, and beneficial effects on the 
heart seems confirmed mechanistically by reduced steatosis 
of the heart30 and improved myocardial blood flow.31
Pioglitazone reduced the composite endpoint of all-
cause mortality, nonfatal MI, and stroke in patients with 
type 2 diabetes who had a high risk of macrovascular 
events, according to Dormandy et al32 in the Prospective 
Pioglitazone Clinical Trial In Macrovascular Events (PRO-
ACTIVE Study). PROACTIVE was a prospective, random-
ized controlled trial that included 5,238 patients with type 2 
diabetes who had evidence of macrovascular disease. Meta-
analysis by Lincoff et al33 confirmed these results, concluding 
that pioglitazone is associated with a significantly lower risk 
of death, MI, or stroke among a diverse population of patients 
with diabetes. Serious CHF was increased by pioglitazone, 
although without an associated increase in mortality. A total 
of 19 trials enrolling 16,390 patients were analyzed. Death, 
MI, or stroke occurred in 375 of 8,554 patients (4.4%) receiv-
ing pioglitazone and 450 of 7,836 patients (5.7%) receiving 
control therapy (HR, 0.82; 95% CI, 0.72–0.94; P = 0.005).
There has been a debate about a possible increase in 
adverse CV events with rosiglitazone since Nissen and 
Wolski34 published their meta-analysis, and a Cochrane 
review35 appears to confirm this. The Food and Drug 
Administration, the European Medicines Agency, and the 
Health Canada have all weighed in and assigned a black 
box warning for an increased risk of ischemic CV events for 
rosiglitazone. No such warning was issued for pioglitazone. 
Moreover, a population cohort study of 40,000 patients36 and 
another study of real-world use by 90,000 patients37 would Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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seem to confirm this difference. The 2 agents appear 
to differ in the way they “turn on” genes, even though 
both agents are PPAR-gamma agonists.38,39 Clinically, 
the 2 agents have different effects on lipid patterns, 
as discussed earlier, thus emphasizing pioglitazone’s 
benefits in practice.
weight gain
In intensively insulin-treated, obese type 2 diabetic patients, 
at equivalent glycemic control, the addition of pioglitazone 
causes greater weight gain, but causes a similar increase 
in body water that is mainly extracellular and interstitial 
compared with intracellular increase with insulin therapy 
alone.40 Pioglitazone also increases the filtered load of 
sodium reabsorbed at the distal nephron, with no net change 
in fractional excretion rate of sodium. From our experience, 
attention to issues and therapies discussed above can keep 
these risks to a minimum.
As has been suggested, there is also some nonedematous 
weight gain associated with TZDs. The agents have been 
shown to increase weight from 2 to 8 lbs in patients; however, 
50% do not experience increased weight and have had 
weight loss if a eucaloric or hypocaloric diet is maintained.41 
With proper dietary reinforcement, TZD-associated weight 
changes may be reduced or even absent.42
The combination of TZDs with antidiabetic agents that 
are weight neutral or that promote weight loss may represent 
an important future direction for therapy.
Weight gain can be obviated with combination 
exenatide administration. Combination of pioglitazone and 
exenatide (Byetta®; Eli Lilly and Amylin, Indianapolis, IN, 
USA) causes nearly as much weight loss (∼4 lb) as with 
exenatide alone (∼5 lbs/30 weeks).14 Weight gain is more 
pronounced when TZDs are combined with sulfonylureas 
or insulin43 versus in combination with metformin44,45 or 
exenatide.46
Bone effects
It appears that pioglitazone is associated with a modest 
increased risk of distal bone fractures in women.47 A let-
ter to physicians issued by Takeda Pharmaceuticals in 
2007 reported an analysis of its pioglitazone clinical trials 
database.48 They compared the incidence of fractures in 
more than 8,100 patients treated with pioglitazone with more 
than 7,400 patients treated with a comparator. The fracture 
incidence calculated was 1.9 fractures per 100 patient 
years in women treated with pioglitazone and 1.1 fractures 
per 100 patient years in women treated with a comparator. 
The observed excess risk of fractures for women in this 
data set on pioglitazone is, therefore, 0.8 fractures per 100 
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patient years of use. There was no increased risk of fractures 
identified in men. A recent large database study (∼18,000 
patients) confirmed a clear but low risk of TZD-associated 
fractures.49
The mechanism is in part related specifically to a TZD 
effect on shifting precursor cell production from osteo-
blasts to fat cells in the bone marrow, resulting in decreased 
bone formation. However, part of the effect seems to be 
related to decreasing insulin resistance by any means, in 
that in doing so, one decreases insulin and amylin (which 
stimulate osteoblast and decrease osteoclast formation), 
thus decreasing bone formation and increasing resorption. 
Moreover, Americans have a high incidence of vitamin D 
deficiency.
Thus, a clinician’s decision to use TZDs in perimeno-
pausal women will depend on weighing the benefits of their 
use in glycemic control, lipid benefit, decreasing insulin 
resistance, and likely reduction in CV outcomes compared 
with a low risk of distal fractures that may be mitigated by 
administration of vitamin D, calcium, and bisphosphonates 
in women at higher risk.
TZDs in combination therapy
Given type 2 diabetes results from a combination of insulin 
resistance and beta cell dysfunction, the combination of a TZD 
and an incretin mimetic offers a combination of characteristics 
(eg, glycemic control, reduced insulin resistance, decreased 
weight, potential cardiovascular benefits, and beta cell 
preservation) that addresses many of the pathophysiologic 
underpinnings of type 2 diabetes. A recent small placebo-
controlled study assessed the effects of exenatide used with 
a TZD with or without metformin. Exenatide demonstrated 
a greater incidence of HbA1c , 7%; greater reductions in 
fasting blood glucose levels, postprandial glucose levels, 
and body weight; and improved beta cell function versus the 
TZD/placebo group. Dual effects on insulin sensitivity (TZD) 
and insulin secretion (exenatide) make the TZD/exenatide 
combination a rational treatment option for patients who 
do not attain glycemic control with a single agent. Studies 
undertaken to evaluate the effects on CV outcomes and the 
potential for prevention of type 2 diabetes with impaired 
glucose tolerance may reveal additional advantages of this 
combination approach.46
If a patient has an HbA1c value of 7.5% or lower, it may be 
possible to achieve a goal HbA1c value of 6.5% with the use 
of monotherapy, according to a recent treatment algorithm 
from the American Association of Clinical Endocrinologists 
(AACE).50 If monotherapy fails to achieve that goal, one 
usually progresses to dual and then to triple therapy, which 
includes the addition of a TZD. If the use of dual therapy 
fails, one might add TZD or glargine – here we suggest the 
advantages of TZD before starting glargine. Earlier combina-
tion therapy, initially, is also a major new recommendation of 
the new AACE guidelines. However, if not at glycemic goals 
with 3 noninsulin agents, insulin therapy should be initiated, 
with or without additional agents.50
We emphasize, however, in our large clinical experience 
that considering a patient a “noninsulin-therapy failure” 
should be reserved for those who avoid intake of concen-
trated sweets. We have observed that too often the insulin 
is started in patients eating sweets, resulting in increased 
weight. These patients also commonly experience recur-
rent hypoglycemia, especially if they avoid sweets for a 
few days, increasing appetite (causing more weight gain), 
and “rebound” hyperglycemia. These patients may then be 
prescribed inappropriate increases in insulin doses for the 
rebound hyperglycemia, leading to a vicious cycle. Thus, 
only when triple therapy fails to achieve glycemic control 
in the patient on the right diet, can one say that it is likely 
that the insulin-secretory capacity of the beta cells has 
exceeded; thus, insulin therapy is needed. One can then 
institute therapy as basal with or without prandial (eg, basal-
bolus insulin).50
Insulin: a brief review
As Nathan et al recently discussed, we have the most clinical 
experience with insulin as it is our oldest medication.51 It is 
the most effective therapy for lowering glycemia, and when 
used in adequate doses, it can decrease elevated HbA1c to, or 
close to, therapeutic goal. Although initial therapy is aimed 
at increasing basal insulin supply with long-acting insulins,50 
patients may also require prandial therapy with short- or 
rapid-acting insulins.50 Insulin analog with longer, nonpeak-
ing profiles decrease the risk of hypoglycemia modestly 
compared with isophane or NPH insulin, and analog with 
very short durations of action reduce the risk of hypoglycemia 
compared with regular insulin, as per discussion of Nathan 
et al.51 Very-rapid-acting and long-acting insulin analogs have 
not been shown to lower HbA1c levels more effectively than 
the older, rapid-acting or intermediate-acting formulations. 
Although insulin has beneficial effects on lipids, it is associ-
ated with weight gain of about 2–4 kg. Weight gain can be 
excessive in patients whose insulin is adjusted to compensate 
for eating more calories than they use. Furthermore, insulin 
therapy is associated with hypoglycemia. The incidence 
of severe hypoglycemia in the intensive treatment group Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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in the DCCT ranged from 2 to 6 times that observed with 
conventional treatment.4
EDIC, the DCCT follow-up, revealed that intensive 
treatment reduced the risk of any CVD event by 42% (95% 
CI, 9%–63%; P = 0.02) and the risk of nonfatal MI, stroke, or 
death from CVD by 57% (95% CI, 12%–79%; P = 0.02).5 The 
decrease in A1C values during the DCCT was significantly 
associated with most of the positive effects of intensive 
treatment on the risk of CVD.
We have also learned that if control is poor with insulin, 
then the risk of death is increased.52 Mechanisms of these 
increased risks, we believe, are associated with insulin in 
patients not well controlled include increased endothelial 
dysfunction, and inflammation, as well as the adverse effects 
of weight gain and hypoglycemia.
TZD vs insulin therapy
Adding insulin or pioglitazone  
when other therapies fail
Aljabri et al compared the efficacy of adding pioglitazone 
or bedtime NPH insulin to maximal doses of metformin/
sulfonylurea in type 2 diabetes patients with poor glucose 
control. In their 62-patient, open-label, randomized, controlled 
trial, they studied type 2 diabetes patients with HbA1c . 8.0%. 
Patients received either pioglitazone or bedtime NPH insulin 
in addition to their usual diabetes medication for 16 weeks.53 
HbA1c levels were lowered to a similar degree in each treat-
ment arm (pioglitazone: −1.9% ± 1.5%; insulin: −2.3% ± 
1.5%; P = 0.32), but hypoglycemia was less common among 
patients who received pioglitazone than among those who 
received insulin (37% vs 68%; P = 0.02). Pioglitazone, but 
not insulin, resulted in an increase in HDL-C levels. Both 
treatments had similar effects on weight, other lipid values, 
blood pressure, and urine microalbumin levels.
Pioglitazone has also shown efficacy among patients 
who failed sulfonylurea. In an open-label, randomized, 
controlled trial of 281 patients with at least 3 months of 
inadequate glycemic control (HbA1c = 7.4%–14.7%) on 
a sulfonylurea. Combination therapy using insulin and 
pioglitazone reduced HbA1c more than either insulin alone 
or adding pioglitazone to sulfonylurea, but resulted in more 
weight gain.54 These findings were similar to those of an 
open-label trial of 217 patients inadequately controlled on 
metformin and sulfonylurea, with each drug dosed at $50% 
of the recommended maximum. Patients were randomized 
to add either insulin glargine or rosiglitazone. Both groups 
had equivalently reduced A1C after 24 weeks (−1.7% for 
glargine vs −1.5% for rosiglitazone).55
Thirty-six patients inadequately controlled on metformin 
and sulfonylurea/meglitinide were randomized to add-on 
therapy with insulin glargine or pioglitazone for 26 weeks. 
The effect on beta cell function was more favorable with 
insulin glargine measured by proinsulin (P = 0.04), while the 
improvement in insulin sensitivity measured by adiponectin 
(P = 0.04) and HDL-C (P , 0.01 vs NS) (all P between 
groups ,0.01) was more favorable in the pioglitazone group. 
The results demonstrate the characteristic differences in the 
effects of insulin glargine and pioglitazone on measures 
of beta cell function, insulin sensitivity, and cardiac load. 
Insulin glargine resulted in better relief of beta cell stress, 
and pioglitazone increased adiponectin and HDL-C and also 
BNP and NT-pro-BNP concentrations.56
An interpretation of the above data might auger for 
avoiding insulin until the patient fails all 3 agents (TZD, 
metformin, and sulfonylurea), as long as one pays attention 
to avoidance of potential side effects of sulfonylurea and 
TZD, and might auger for use of an incretin instead of an 
oral hypoglycemic agent to avoid hypoglycemia and undue 
weight gain.
TZD plus insulin
However, if a patient is not at goal with 3 noninsulin 
therapies, there is great logic and clinical value to keeping 
a TZD on board as insulin therapy is initiated, as long as 
attention is paid to potential downsides.
Scheen wrote that from theoretical point of view, the 
combination of an insulin sensitizer (a glitazone) with 
exogenous insulin is appealing.20 This is for several reasons 
including a lower insulin dose is likely, improvement of the 
patient’s metabolic control, improvements in lipid profile, 
and even the possibility of eliminating the need for insulin 
in those not given insulin sensitizers prior to starting insulin. 
In addition, Scheen reported that glitazones may exert some 
beneficial effects beyond improvement of glycemic control, 
especially by improving cardiovascular outcomes, possibly 
by obtaining the beneficial effects that it has on inflammation, 
endothelial dysfunction, and lipids.20 Similarly, Yamanouchi57 
also discusses benefits, safety issues (and mitigation of such), 
and a significant potential atherosclerotic benefit to using 
pioglitazone with insulin.
A study revealed that pioglitazone significantly reduced 
(P , 0.05) insulin dose requirements 2 weeks after initiation 
of treatment. At the end of the study, relative to baseline, 
pioglitazone reduced daily insulin dosages by 12.0 U 
(P , 0.001), a 21.5% (12.0/55.8 U at baseline) group mean 
average reduction. Pioglitazone also significantly increased Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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HDL-C levels, decreased triglyceride levels, shifted LDL 
particle concentrations from small to large, and increased 
mean LDL particle size.58 In the PROACTIVE trial, a third of 
the patients were on insulin at baseline, about a half received 
pioglizazone. Those patients on insulin and pioglizazone 
needed ~20% less insulin, had a simplified regimen, had a 
greater drop in HbA1c (0.93 vs 0.45) and 9% were able to 
stop insulin.59
Hypoglycemia, edema, and weight gain often accompany 
the use of insulin and TZDs60,62 and must assiduously be 
addressed when maintaining TZDs with insulin. Scheen 
reported that hypoglycemia usually occurs in the first few days 
or weeks of combined therapy and could be quite easily avoided 
by an appropriate reduction in daily insulin dosages.20
In the randomized, controlled trial comparing 15 and 
30 mg of pioglitazone and placebo, in combination with 
insulin, patients in the placebo treatment group in general 
experienced no alterations in body weight (−0.04 kg mean 
change from baseline).63
Weight gain associated with glitazones in insulin-treated 
patients with type 2 diabetes appears to be similar to or even 
slightly higher than the weight gain reported in monotherapy 
or when glitazones are given in combination with metformin 
or sulphonylureas. In the randomized, controlled trial 
comparing 15 and 30 mg pioglitazone and placebo, in 
combination with insulin, edema was reported in 7.0% of 
patients in the placebo plus insulin arm versus 12.6% in the 
15 mg pioglitazone plus insulin arm and 17.6% in the 30 mg 
pioglitazone plus insulin group.64
If one pays attention to potential risks for each agent 
independently, one should be able to avoid, in the majority 
of clinical situations, the potential additive risks. Thus, 
for TZDs, advise a low-salt diet, do not use the drug in 
patients with class 3/4 CHF, avoid the drug in patients with 
significant preexisting edema from other causes (eg, venous 
insufficiency), and advise a eucaloric diet. For insulin, similar 
strategy regarding a low-salt diet to avoid insulin-induced 
edema, a eucaloric no-concentrated sweets diet, and an appro-
priate dose adjusting to avoid hypoglycemia will obviate 
undue side effects of combining the 2 agents.
Adding TZD to existing insulin
In some situations, patients are on insulin and the question 
arises regarding the value of adding a TZD. This was 
evaluated in 566 patients receiving stable insulin regimens 
for .30 days who had HbA1c levels . 8.0% and plasma 
C-peptide levels . 0.7 µg/L. They were randomized to 
receive once-daily 15 or 30 mg pioglitazone, or placebo in a 
16-week multicenter, double-blind, placebo-controlled trial. 
Patients receiving 15 or 30 mg pioglitazone had statistically 
significant decreases in HbA1c levels compared with baseline 
(−1.0% and −1.3%, respectively; P , 0.0001).20
Mattoo et al sought to determine the effect of 30 mg 
  pioglitazone plus insulin versus placebo plus insulin on gly-
cemic control, serum lipid profile, and selected cardiovascular 
risk factors in patients with type 2 diabetes whose disease was 
inadequately controlled with insulin therapy alone despite 
efforts to intensify such treatment.65 They randomized 289 
patients in the 6-month, double-blind, prospective, multi-
center, placebo-controlled, parallel-group study. After an 
insulin intensification period, the patients with HbA1c $ 7.0% 
were randomized to pioglitazone plus insulin or placebo plus 
insulin. Placebo plus insulin produced no significant changes 
in HbA1c or fasting plasma glucose. The between-treatment 
differences for A1C (−0.55%; P , 0.002) and fasting plasma 
glucose (−1.80 mmol/L; P , 0.002) occurred despite a 
reduction of insulin dose in the pioglitazone plus insulin 
group from baseline (−0.16 U/d kg; P , 0.002). Significant 
between-group differences were observed for HDL-C and 
high-sensitivity C-reactive protein. Adding pioglitazone to 
insulin in these study patients with type 2 diabetes whose dis-
ease was inadequately controlled with insulin monotherapy 
further improved their glycemic control.65
The Pioglitazone 343 Study Group66 sought to determine 
the effects of pioglitazone treatment combined with insulin 
on glucose and lipid metabolism in patients with type 2 
diabetes. In a multicenter, double-blind study, 690 patients 
with diabetes poorly controlled with a stable insulin dose 
were randomized to 30 or 45 mg pioglitazone once-daily 
for 24 weeks. Statistically significant, dose-dependent mean 
decreases from baseline were seen in the 30- and 45-mg 
pioglitazone groups for HbA1c and fasting plasma glucose. 
Insulin dosage also decreased significantly from baseline. 
Decreases in triglycerides, very LDL-cholesterol, and free 
fatty acids and increases in HDL-C were also observed from 
baseline.66
Another 30-mg pioglitazone regimen with insulin was 
previously shown in a 16-week study to be generally well toler-
ated and resulted in clinically relevant improvements in both 
glucose and lipid metabolism. Successful termination of insulin 
therapy with the addition of pioglitazone has been seen.67
TZD-based oral combination therapy has been shown to 
efficiently and safely substitute for relatively high-dose insulin 
injection therapy in some patients with type 2 diabetes. The 
high success rate of switching from insulin treatment to oral 
agent therapy is mainly due to the pioglitazone-mediated Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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improvement of insulin resistance, improving beta-cell 
function. This study looked at 36 subjects, with an average 
insulin dose of 0.46 ± 0.17 U/kg body weight, a duration of 
insulin therapy of 6.1 ± 8.2 years, and an average HbA1c of 
6.8 ± 1.3%, who were switched from insulin injection therapy 
to pioglitazone, glimepiride, and voglibose combination ther-
apy. The success rate of switch therapy was 83% (30/36).68
value of getting off insulin
Pioglitazone may induce a beneficial effect on atherosclerosis69,70 
compared with insulin because treatment that improved 
insulin resistance reduced the recurrence of acute coronary 
syndrome more effectively than insulin upregulation therapy.71 
Moreover, hyperinsulinemia has been reported to be an inde-
pendent risk factor for macrovascular disease.72 Although 
intensive glucose-lowering therapy comprising insulin injec-
tion did not show any preventive effect on stroke, pioglitazone 
significantly reduced the recurrence of stroke by 47%.73
Conclusions
Insulin resistance and obesity, the key components of type 2 
diabetes, increase the incidence of CVD in the type 2 diabetes 
patients. Insulin resistance is a major etiological factor in 
type 2 diabetes, and of course diabetes accentuates the CV 
risk factors of the insulin resistance syndrome.
TZDs represent an effective tool for targeting some features of 
this increased risk as they decrease insulin resistance and therefore 
can prevent and/or delay diabetes progression. If we can alter the 
natural history of diabetes, we may be able to lessen microvascu-
lar and macrovascular complications. To achieve this, we must 
improve CV risk factors in type 2 diabetes patients. In this regard, 
pioglitazone has been shown to have beneficial effects on the lipid 
profile, as well as likely other associated CV benefits.
Clinical value accrues from adding TZDs to noninsulin 
therapy and keeping TZDs on board among those who start 
insulin therapy, and adding TZDs to existing insulin therapy. 
It is important for the clinician to recognize potential side 
effects and avoid use among inappropriate patients. When 
using pioglitazone, the patient should be seen regularly to 
quickly mitigate any side effects.
Patients taking insulin may benefit from the addition 
of a TZD by achieving weight loss, less hypoglycemia, an 
improvement in endothelial function, and a reduction in 
inflammation. Some patients may even come off insulin with 
pioglitazone treatment.
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